Toxicité hématologique sévère du linezolide au cours du traitement de la tuberculose pharmacorésistante : A propos de deux(2) cas au service de Pneumo-Phtisiologie du CHU de Conakry

Diallo, B. D; Barry, A. O; Sylla, D; Camara, A; Diallo, O. H; Camara, M. H; Touré, D; Magassouba, A. S; Camara, L. M.
Journal of African Clinical Cases and Reviews/Journal Africain des Cas Cliniques et Revues ; 3(4): 328-333, 2019.
Artículo en Francés | AIM | ID: biblio-1264287

Documentos relacionados

  1. Model-based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug-resistant tuberculosis.
  2. Regimens for Drug-Resistant Tuberculosis.
  3. Regimens for Drug-Resistant Tuberculosis.
  4. Regimens for Drug-Resistant Tuberculosis. Reply.
  5. More Tailored Approaches to Tuberculosis Treatment and Prevention.
  6. [Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
  7. New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.
  8. Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment.
  9. Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment.
  10. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.